

IN THIS ISSUE

- 2 News**
Expert panel weighs in on nesiritide safety, 4
Statins may prevent atrial fib in patients with impaired LV function, 5
- 9 Interventional Cardiology**
Lubricant eases stents into tight coronary arteries.
- 10 Hypertension**
Hard-to-treat hypertensives respond to simple regimen.
- 11 Heart Failure**
Candesartan cleared for use in heart failure patients on ACE inhibitors.
- 12 Arrhythmias & Electrophysiology**
Rhythm control improves quality of life in patients with atrial fib.
- 14 Surgery**
Mild to moderate CAD is not a barrier to lung transplant.
- 15 CAD & Atherosclerosis**
Low LDL may mask cholesterol sensitivity threat, 16
- 18 Opinion**
Letters
- 20 Practice Trends**
Policy & Practice
FDA drug safety program is under voluntary review, 21
- 23 On the Beat**
Reader Services
Classifieds, 22
Index of Advertisers, 23

EDITORIAL ADVISORY BOARD

- SIDNEY GOLDSTEIN, M.D.**, Michigan
Medical Editor
- JONATHAN ABRAMS, M.D.**, New Mexico
Associate Medical Editor
- ERIC R. BATES, M.D.**, Michigan
- GEORGE BELLER, M.D.**, Virginia
- STEVEN F. BOLLING, M.D.**, Michigan
- ROBERT M. CALIFF, M.D.**, North Carolina
- PRAKASH C. DEEDWANIA, M.D.**, California
- KIM A. EAGLE, M.D.**, MICHIGAN
- JAMES J. FERGUSON, III, M.D.**, Texas
- JOHN FLACK, M.D.**, Michigan
- THOMAS D. GILES, M.D.**, Louisiana
- ANTONIO M. GOTTO, Jr., M.D.**, New York
- DAVID L. HAYES, M.D.**, Minnesota
- DAVID R. HOLMES, Jr., M.D.**, Minnesota
- BARRY M. MASSIE, M.D.**, California
- CHRISTOPHER M. O'CONNOR, M.D.**, North Carolina
- NATESA G. PANDIAN, M.D.**, Massachusetts
- ILEANA L. PIÑA, M.D.**, Ohio
- OTELIO RANDALL, M.D.**, Washington, D.C.
- THOMAS J. RYAN, M.D.**, Massachusetts
- HANI N. SABBAH, Ph.D.**, Michigan
- LESLIE ANNE SAXON, M.D.**, California
- DAVID H. SPODICK, M.D.**, Massachusetts
- NEIL J. STONE, M.D.**, Illinois
- PAUL D. THOMPSON, M.D.**, Connecticut
- ROBERTA WILLIAMS, M.D.**, California

HEART OF THE MATTER

BiDil for Everyone

With the approval of BiDil for the treatment of heart failure in African Americans, the Food and Drug Administration has essentially excluded the use of this combination of isosorbide dinitrate and hydralazine in non-African Americans.

In the African-American Heart Failure Trial (A-HeFT), BiDil decreased mortality in 1,050 exclusively African American patients with New York Heart Association class III and IV heart failure randomized to the drug or a placebo. Most impressively, this benefit occurred in the presence of concomitant therapy with ACE inhibitors and β -blockers within 10 months (N. Engl. J. Med. 2004;351:2049-57).

A major question remains whether this approval should indicate that its use be limited to African American patients only or extended also to all patients. Now that it is approved, it will almost certainly be used in heart failure patients regardless of race. The two drugs are readily available as generic preparations in any pharmacy.

Much has been made of the observation that the antihypertensive effects of


ACE inhibitors are less in African Americans than in whites. In addition, the mortality benefit observed in African Americans, compared with whites, in the Vasodilator Heart Failure Trial (V-HeFT I) provides additional foundation for A-HeFT. If a differential blood pressure response was the cause of improved response in A-HeFT, there is little evidence for that. Very minimal decreases of systolic (0.7 mm Hg) and diastolic (1.6 mm Hg) pressure in diastole were seen in the BiDil-treated patients.

It has been suggested that the benefit of BiDil may be related to the antioxidant effect of hydralazine. This theory is supported in part by observation that African Americans may be deficient in nitric oxide, a major source of oxidant metabolism. A lack of nitric oxide at the cellular level as a result of a decrease in endothelial nitric oxide synthase (eNOS) is thought to be a potential putative process of heart failure. If African Americans with heart failure were more deficient in eNOS, they could be more likely to benefit from chronic therapy with BiDil. However, if not, one would expect the effect to be the same, regardless of race.

Some aspects of the therapy are puzzling. The drug was rather poorly tolerated, with only 68% of the BiDil patients staying on the drug, compared with 89% in the placebo group during the 10 months of follow-up. Much of this was presumably due to headache and dizziness, which occurred in 48% and 29% of the patients, respectively. In addition, long-term hydralazine use has been reported to result in a lupus-like syndrome with arthritis at doses greater than 200 mg/day, particularly in patients with renal dysfunction. The dose used in A-HeFT was 225 mg/day. Unfortunately, the duration A-HeFT was short, owing to its observed benefit.

The A-HeFT findings provide a new approach to treating heart failure, regardless of race. If the antioxidant hypothesis is correct, its application should not be limited to African Americans. Given that previous clinical trials in heart failure—which, unfortunately, have been dominated by whites—have been applied to all heart failure patients, regardless of race, it is reasonable that the results in A-HeFT should also be applied to all heart failure patients. ■

DR. GOLDSTEIN, *medical editor of Cardiology News*, is professor of medicine at Wayne State University and division head, emeritus, of cardiovascular medicine at Henry Ford Hospital, Detroit.



BY SIDNEY GOLDSTEIN, M.D.

Cardiology News

President, IMNG Alan J. Imhoff

Executive Director, Operations Jim Chicca

Director, Production/Manufacturing Yvonne Evans

Production Manager Judi Sheffer

Production Specialists Anthony Draper, Thomas Humphrey, Rebecca Slebodnik, Mary D. Templin

Senior Systems Administrator Lee J. Unger

Application Systems Specialist Doug Sullivan

Systems Administrator Drew Mintz

Operations Assistant Melissa Kasimatis

Art Director Louise A. Koenig

Assistant Design Supervisor Elizabeth B. Lobdell

Design Staff Sarah L. Gallant, Forhad S. Hossain, Julie Keller, Angie Ries

Photo Editors Lolita Jones, Vivian E. Lee, James E. Reinaker

Project Manager Susan D. Hite

Assignments Coordinator Megan Evans

Departmental Coordinator Vicki Long

Editorial Coordinator Daniela Silva

H.R. Manager Philip Cooksey

Regional Manager of Facilities Chris Horne

Receptionist YoLanda L. Mitchell

Address Changes Fax change of address (with old mailing label) to 301-816-8736 or e-mail change to subs@elsevier.com

CARDIOLOGY NEWS is an independent newspaper that provides the practicing specialist with timely and relevant news and commentary about clinical developments in the field and about the impact of health care policy on the specialty and the physician's practice.

The ideas and opinions expressed in CARDIOLOGY NEWS do not necessarily reflect those of the Publisher. Elsevier Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

Editor-in-Chief Mary Jo M. Dales

Publication Editor Catherine Hackett

Publication Associate Editor Mark S. Lesney

Senior Editors Kathryn DeMott, Denise Fulton, Gina L. Henderson, Sally Koch Kubetin, Teresa Lassman, Catherine Cooper Nellist, Calvin Pierce, Terry Rudd, Kathy Scarbeck, Elizabeth Wood

Associate Editors Christina Chase, Jay C. Cherniak, Richard Franki, Deeanna Franklin, Randall Frey, Joyce Frieden, Gwendolyn Hall, Amy Pfeiffer, Jennifer Silverman, Robin L. Turner

Bureaus Betsy Bates (Los Angeles), Sherry Boschert (San Francisco), Doug Brunk (San Diego), Robert Finn (San Francisco), Bruce Jancin (Denver), Kate Johnson (Montreal), Timothy F. Kirn (Sacramento), Jane Salodof MacNeil (Southwest), Diana Mahoney (New England), Damian McNamara (Miami), Michele G. Sullivan (Mid-Atlantic), Nancy Walsh (New York), Patrice Wendling (Chicago), Sharon Worcester (Tallahassee), Mitchel L. Zoler (Philadelphia)

Senior Writers Jeff Evans, Kevin Foley, Elizabeth Mechatie, Mary Ellen Schneider, Heidi Splete, Miriam E. Tucker, Kerri Wachter

Copy Chief Felicia R. Black

Copy Editors John R. Bell, Therese Borden, Virginia Ingram-Wells, Rachel Keith, Jane Locastro, Carol Nicotera-Ward

Editorial Offices 12230 Wilkins Ave., Rockville, MD 20852, 800-445-6975, cardiologynews@elsevier.com



INTERNATIONAL MEDICAL NEWS GROUP



BPA

V.P., Med. Ed./Bus. Development

Sylvia H. Reitman

Program Manager, Med. Ed. Sara M. Hagan

Senior Director, Marketing/Research

Janice Theobald

Marketing Associate Jennifer Savo

Sales Director Jeffrey R. Davis

Executive Director, Business Operations

Bari Edwards

Bus. Manager Brian O'Connor

Adv. Services Manager Joan Friedman

Credit Supervisor Patricia H. Ramsey

Manager, Administration/Conventions

Lynne Kalish

Sales Assistant Kathy Craine

Receptionist Linda Wilson

Sales Manager, Primary Care Mark E. Altier,

973-290-8220, m.altier@elsevier.com

National Account Managers Sue Fagan,

973-290-8226, s.fagan@elsevier.com;

Barbara Napoli, 973-290-8224, b.napoli@

elsevier.com; Christy Tetterton, 973-290-

8231, c.tetterton@elsevier.com

Advertising Offices 60 Columbia Rd., Bldg. B,

Morristown, NJ 07960, 973-290-8200,

fax 973-290-8250

Classified Sales Manager Robin Cryan, 212-

633-3160, r.cryan@elsevier.com

Classified Advertising Offices 360 Park Ave.

South, 9th Floor, New York, NY 10010,

800-379-8785, fax 212-633-3820

Reprints Call 301-816-8726

POSTMASTER Send changes of address (with

old mailing label) to Circulation, CARDIOLOGY

NEWS, 12230 Wilkins Ave., Rockville, MD

20852.

CARDIOLOGY NEWS (ISSN 1544-8800) is published

monthly by Elsevier Inc., 60 Columbia Rd., Building

B, Morristown, NJ 07960, 973-290-8200, fax 973-

290-8250. ©Copyright 2005, by Elsevier Inc.